Design of the β3-Adrenergic Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure Trial

Combined pre-and post-capillary hypertension (CpcPH) is a relatively common complication of heart failure (HF) associated with a poor prognosis. Currently, there is no specific therapy approved for this entity. Recently, treatment with beta-3 adrenergic receptor (β3AR) agonists was able to improve p...

Descripción completa

Detalles Bibliográficos
Autores: García Lunar, Isabel, Blanco Vich, Isabel, Fernández Friera, Leticia, Prat González, Susanna, Jordà Burgos, Paloma, Sánchez, Javier, Pereda, Daniel, Pujadas, Sandra, Rivas Lasarte, Mercedes, Solé González, Eduard, Vázquez, Jorge, Blázquez Bermejo, Zorba, García Picart, Juan, Caravaca Pérez. Pedro, Escalera, Noemí, Garcia Pavia, Pablo, Delgado Jiménez, Juan, Segovia Cubero, Javier, Fuster, Valentín, Roig i Minguell, Eulàlia, Barberà i Mir, Joan Albert, Ibáñez Cabeza, Borja, García Álvarez, Ana
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2020
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/183423
Acceso en línea:https://hdl.handle.net/2445/183423
Access Level:acceso abierto
Palabra clave:Simpatomimètics
Hipertensió pulmonar
Sympathomimetic agents
Pulmonary hypertension
Descripción
Sumario:Combined pre-and post-capillary hypertension (CpcPH) is a relatively common complication of heart failure (HF) associated with a poor prognosis. Currently, there is no specific therapy approved for this entity. Recently, treatment with beta-3 adrenergic receptor (β3AR) agonists was able to improve pulmonary hemodynamics and right ventricular (RV) performance in a translational, large animal model of chronic PH. The authors present the design of a phase II randomized clinical trial that tests the benefits of mirabegron (a clinically available β3AR agonist) in patients with CpcPH due to HF. The effect of β3AR treatment will be evaluated on pulmonary hemodynamics, as well as clinical, biochemical, and advanced cardiac imaging parameters. (Beta3 Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure [SPHERE-HF]; NCT02775539).

Similares en LA Referencia